Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism

Clinical and Experimental Immunology

Volumn 116, Issue 2, 1999, Pages 326-331

  Huang, Y H ^a   Schafer Elinder L ^b   Wu, R ^a   Claesson, H E ^b   Frostegard J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atherosclerosis; Cytokines; Lysophosphatidylcholine; Oxidized LDL; Platelet activating factor

Indexed keywords

ANTIBODY; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONIC ACID; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0032948306     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00871.x     Document Type: Article

References (41)

1. 1 Quinn MT, Parthasarathy S, Fong GL, Steinberg D. Oxidatively modified low density lipoprotein: a potential role in recruitment and retention of monocytes/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84:2995-8.
2. 2 Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Eng J Med 1989; 320:915-24.
3. 3 Frostegård J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified low density lipoprotein increases the adhesive properties of vascular endothelial cells. Atherosclerosis 1991; 90:119-26.
4. 4 Frostegård J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low-density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87:904-8.
5. 5 Uyemura K, Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97:2130-8.
6. 6 Palinski W, Rosenfeld ME, Ylä-Herttuala S et al. Low density lipoprotein undergoes modification in vivo. Proc Natl Acad Sci USA 1989; 86:1372-6.
7. 7 Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339:883-7.
8. 8 Frostegård J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T cell activation by oxidized low density lipoprotein. Arteriosclerosis Thrombosis 1992; 12:461-7.
9. 9 Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92:3893-7.
10. 10 Huang YH, Rönnelid J, Frostegård J. Oxidized LDL induces enhanced antibody formation and MHC class II dependent IFN-gamma production in lymphocytes from healthy individuals. Arteriosclerosis, Thromb Vasc Biol 1995; 15:1577-83.
11. 11 Watson AD, Navab M, Hama SY et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95:774-82.
12. 12 Frostegård J, Huang YH, Rönnelid J, Schäfer-Elinder L. PAF and oxidized LDL induce immune activation by a common mechanism. Arteriosclerosis, Thrombosis Vasc Biol 1997; 17:963-8.
13. 13 Rosenfeldt ME, Palinski W, Ylä-Herttuala S, Butler S, Parthasarathy S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990; 10:349.
14. 14 Björkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L, Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arteriosclerosis Thrombosis 1991; 11:15-22.
15. 15 Esterbauer H, Jürgens G, Quehenberger O, Koller E. Autooxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 1987; 28:495-509.
16. 16 Brown MS, Kovanen P, Goldstein J. Regulation of plasma cholesterol by lipoprotein receptors. Sci 1981; 212:628-35.
17. 17 Brown MS, Basu SK, Falck JR, Ho YK, Goldstein JL The scavenger cell pathway for lipoprotein degradation. Specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. J Supramol Struct 1980; 13:67-81.
18. 18 Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988; 85:2805-9.
19. 19 McMurray HF, Parthasarathy S, Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 1993; 92:1004-8.
20. 20 Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90:1138-44.
21. 21 Wu R, Huang YH, Schäfer-Elinder L, Frostegård J. Lysophosphatidylcholine is involved in the antigenicity of oxLDL, Arteriosclerosis Thromb Vasc Biol 1998; 18:626-30.
22. 22 Heuer H, Birke F, Brandt K, Muacevic G, Weber KH. Biological characterization of the enantiomeric hetrazepines of the PAF-antagonist WEB 2170. Prostaglandins 1988; 35:847.
23. 23 Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony Ö. Reverse ELISPOT assay for colonel analysis of cytokine production. I. Enumeration of gamma-inferferon-secreting cells. J Immunol Methods 1988; 110:29-36.
24. 24 Rönnelid J, Huang YH, Norrlander T, Rogberg S, Nilsson B, Gustafsson R, Klareskog L. Short term kinetics of the humoral anti-Clq response in SLE using the ELISPOT method: fast decline in production in response to steroids. Scand J Imunol 1994; 40:243-50.
25. 25 Czerkinsky C, Nilsson L, Nygren H, Ouchterlony Ö, Tarkowski A. A solid-phase enzyme linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983; 65:109-21.
26. 26 Schäfer-Elinder L, Hedin U, Dumitrescu A, Larsson P, Frostegǎrd J, Claesson HE. Presence of different isoforms of phospholipase A2 in tissue slices from atherosclerotic carotid plaque. Arteriosclerosis Thromb Vasc Biol 1997; 17:2257-62.
27. 27 Tokumura A. A family of phospholipid autacoids: occurrence, metabolism and bioactions. Prog Lipid Res 1995; 34:151-84.
28. 28 Sparrow CP, Parthasarathy S, Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res 1988; 29:745-53.
29. 2+ signiling via the platelet-activating factor receptor in macrophages. Am J Physiol 1997; 272:17-24.
30. 30 Trinchieri G, Gerosa F. Immunoregulation by interleukin-12. J Leukocyte Biol 1996; 59:505-11.
31. 31 Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341:923-5.
32. 32 Hörkkö S, Miller E, Dudl E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Inv 1996; 98:815-25.
33. 33 Koga T, Wand-Wurttenberger A, De Bruyn J, Munk ME, Schoel B, Kaufmann SH. T cells against a bacterial heat shock protein recognize stressed macrophages. Sci 1989; 245:1112-5.
34. 34 Frostegård J, Kjellman B, Gidlund M, Andersson B, Jindal S, Kiessling R. Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis 1996; 121:93-103.
35. 35 Frostegård J, Lemne C, Andersson B, Kiessling R, de Faire U, Association of serum antibodies to heat shock protein 65 with border-line hypertension. Hypertension 1997; 29:40-44.
36. 36 Xu Q, Willeit J, Marosi M et al. Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lancet 1993; 341:255-9.
37. 37 Hughes H, Mathews B, Lenz ML, Guyton JR. Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol. Arterioscler Thromb 1994; 14:1177-85.
38. 38 Lundahl J, Hallden G, Hallgren M, Skold CM, Hed J. Altered expression of CD11b/CD18 and CD62L on human monocytes after cell preparation procedures. J Immunol Methods 1995; 180:93-100.
39. 39 Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhihits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91:4854-8.
40. 40 Frostegård J, Wu R, Haegerstrand A, Patarroyo M, Lefvert AK, Nilsson J. Mononuclear leucocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial expression of adhesion molecules. Atherosclerosis 1993; 103:213-9.
41. 41 Sasaki Y, Asaoka Y, Nishizuka Y. Potentiation of diacylglycerol-induced activation of protein kinase C by lysophospholipids. Subspecies difference. FEBS Letters 1993; 320:47-51.